Prescribed List as at 1 February 2022

Information about the publication of Ministerial Decisions

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision
providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 12 January 2022:

Decision Reference: MD-S-2022-0001
Decision Summary Title :	DS Prescribed list as of 1 February 2022		Date of Decision Summary:	7 January 2022
Decision Summary Author:	Policy Principal		Decision Summary: Public or Exempt?	Public
Type of Report: Oral or Written?	Written		Person Giving Oral Report:	NA
Written Report Title :	WR report PBAC 11 November 2021		Date of Written Report:	5 January 2022
Written Report Author:	Prescribing Advisor		Written Report: Public or Exempt?	Public
Subject: Changes to be made to the Prescribed List (Jersey) as of 1 February 2022
Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 February 2022 (unless stated otherwise) as set out in the accompanying report and supporting document.
Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations: 1. Items to be added to the Prescribed List from 1 February 2022 1.1 Ferric maltol (iron 30mg) capsules for the treatment of iron deficiency anaemia in patients who have failed to tolerate two other oral iron supplements and would otherwise require intravenous iron therapy. 1.2 Lacosamide 50mg, 100mg, 150mg, 200mg tablets; 10mg/ml oral solution sugar free for the treatment of focal seizures in adults and children following initiation by a neurologist 1.3 Ciclesonide 80mcg, 160mcg inhaler for the prevention of asthma in adults and children (aged 12 years and older) 1.4 Trazodone 50mg tablets as an additional strength for a medicine already included in the List 1.5 Hydroxychloroquine 300mg tablets as an additional strength for a medicine already included in the List 2. Items to be removed from the Prescribed List from 1 May 2022 following discontinuation 2.1 Ethinylestradiol 20microgram / Norethisterone acetate 1mg tablets; Ethinylestradiol 30microgram / Norethisterone acetate 1.5mg tablets; Ethinylestradiol 35microgram / Norethisterone 500microgram tablets 2.2 Fluocinolone acetonide 0.0025% cream (Synalar 1 in 10 dilution) 3. Items to be removed from the Prescribed List from 1 August 2022 following consultation with healthcare professionals 3.1 Ascorbic acid 100mg tablets 3.2 Ascorbic acid 500mg tablets (NB Ascorbic acid 500mg chewable tablets will remain in the List where required for co-prescribing with methenamine) 3.3 Ascorbic acid 50mg tablets 3.4 Vitamin B compound strong tablets 3.5 Vitamins capsules 4. Items not recommended for inclusion in the Prescribed List 4.1 Aripiprazole 1mg/ml oral solution requested as an additional pharmaceutical form for a medicine already included in the List 4.2 Paravit-CF capsules 5. Other recommendations 5.1 Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices (Saxenda brand) as an adjunct to weight management – following consultation, the Committee recommended that this product should remain on the Prescribed List subject to starting and stopping criteria. The above recommendations reflect current evidence and expert advice and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.
Resource Implications: The overall financial impact of the above changes is expected to be a cost increase of around £10,000 pa.
Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.
Signature:		Position: Minister
Date Signed:		Date of Decision (If different from Date Signed):